Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Nature of Relevant Financial Relationship Last Name Role in Activity Commercial Interest What Was Received For What Role

Abramson Speaker  AbbVie , Daiichi Sankyo, Eisai  Consulting Fee  Advisory Board

Ali Planning Committee  , Tesaro  Honorarium  Speakers Bureau Moderator/Planning Bhangoo  None  N/A  N/A Committee Moderator/Planning Bollin  None  N/A  N/A Committee  Alexion,  Honorarium  Advisory Board Chaturvedi Speaker  Shire (Takeda)  Research Funding  Research  Array, Bristol Myers‐Squibb,  Honorarium  Consultant Davies Speaker , Roche()  Research Grand  Principle Investigator  Nanostring  Astra‐Zeneca, Bayer Boehringer‐Ingelheim, Bristol‐ Myer‐Squibb, Daiichi‐Sankyo, Eli‐Lilly, Glaxo‐Smith‐Kline, , Janssen, Sanofi‐  Consulting  Consulting /Speaking Eikelboom Speaker Aventis, Servier. Fees/Honorarium  Research  Astra‐Zeneca, Bayer,  Grants/In‐kind Support Grants/Study Supplies Boehringer‐Ingelheim, Bristol‐ Myer‐Squibb, Glaxo‐Smith‐ Kline, Pfizer, Janssen, Sanofi‐ Aventis  Abbvie, Bayer, , Denovo Biopharma, Gilead, OptumRx, Karyopharm, Pharmacyclics/ Janssen, Spectrum  Abbvie, Acerta, Celgene, Gilead, Genentech/Roche,  Honorarium  Consultant Flowers Speaker Janssen Pharmaceutical,  Grants  Research Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation  , Amgen, Prothena Corp,  Consultant WebMD  Consulting Fees  Speaker  Amgen, Celgene, Janssen,  Honorarium  Protocol Johnson & Johnson,  Honorarium Development Gertz Speaker Medscape, Pharmacyclics,  Grants  Advisory Board Physicians Education  Grants  Investigator Resource, Research to Practice  Honorarium  Drug Safety Monitoring Board  Appellees, Annexon  Janssen, Spectrum Z:\Clinical Research Services\Conference Folder\Conferences\Annual Courses\HemOnc 202\2020\Faculty\Disclosures\5 Faculty Disclosure Grid for Onsite‐ HEMONC2020.docx

 Amyloidosis Foundation, International Waldenstrom Foundation  AbbVie Inc.  ATHN, CDC, HRSA  Clinical Trial/Database  Subrecipient PI  Baxter/Shire, NIH, PCORI Support  Site for Multi‐Center Green Speaker  North American Thrombosis  Research Grant Trial Forum  Honorarium  Speaker/Panel  Audro Biotech, Bristol‐Myers Squibb, Halozyme, Inc, Ipsen, Rafael Pharmaceuticals, Inc.,  Honorarium  Advisory Board Hecht Speaker Roche  Grants  Research Support  AbbVie Inc., Advaxis, Amgen, Forty Seven Inc., Halozyme, Inc., Merck, Novartis  AstraZeneca, Bristol‐Myers Squibb, GlaxoSmithKline, Guardant Health, Kairos Venture Investments, BrightPath Biotherapeutics, Hengrui Therapeutics, Eli Lilly, Spectrum, EMD Serono,  Consulting & Advisory Roche, Foundation One  Consulting Fees Board Medicine, EMD Serono Heymach Speaker  Research Grants  Research  NIH/NCI, American Cancer  Royalties & Licensing  Research Patents Society, Cancer Prevention & with Organization Research Institute of Texas, AACR Johnson & Johnson Lung Cancer, AstraZeneca, Spectrum, Checkmate Pharmaceuticals  Spectrum & oBi ‐Tree Systems, Inc.  Aptitude Health, Astellas, Epics, Genentech, PER,  Speaker Research to Practice &  Honoraria  Consultant/Advisory Sanofi/Genzyme  Honoraria Board Hussain Speaker  AstraZeneca, Bayer, Pfizer;  Research Grants  Research (funding to Genentech institution)  AstraZeneca, Bayer, Genentech, Pfizer  AbbVie, Adaptive Jain Speaker , AstraZeneca,  Honorarium  Consultant Janssen, Pharmacyclics  AbbVie Inc., Agios Amgen, Ariad, Astex, Bristol‐Myers Squibb, Cyclacel, Daiichi‐ Sankyo, Immunogen, Jazz,  Research Grants  Research Kantarjian Speaker Novartis, Pfizer  Honorarium  Speakers Bureau  AbbVie, Actinium, Agios Amgen, Immunoggen, Orsinex, Pfizer, Takeda

Kelton Speaker  None  N/A  N/A

Khan Speaker  None  N/A  N/A

 Amgen, EMD Serono Inc.,  Grants  Research Kosty Course Director Genentech, Merck  Consulting Fees  Consultant  Biocept

 Novo Nordisk, Shire BioMarin  Honorarium  Advisory Board Ma Speaker  Shire  Research Funding  Principle Investigator  Accordant  Consulting Fees  Consulting  Genentech, Gilead/Kite, Moderator/Planning  Honorarium  Advisory Board Mahindra Oncopeptides Committee  Honorarium  Speakers Bureau  Amgen, Janssen, Sanofi  Kite Pharma, a Gilead Company; Celgene; and Juno  Clinical Trial PI Therapeutics, a Celgene/BMS  Inventor of treatment Company  Research Funding methodologies  , a  Royalties/licensing fees  Participation in Celgene/BMS Company for Patents licensed and advisory board Maloney Speaker  BioLine RX; Kite Pharma, a pending and/or trial‐specific Gilead Company; Gilead;  Honoraria data monitoring Novartis; Juno Therapeutics, a  Stock options committee meetings Celgene/BMS company;  Scientific Advisory Celgene, a BMS Company; Board member and Pharmacyclics  A2 Biotherapeutics

Malpica Castillo Speaker  None  N/A  N/A

Mason Moderator  None  N/A  N/A

 AstraZeneca, Bristol‐Myers Squibb, Genentech, Geonomic Health,  Honorarium  Advisory Board McArthur Speaker Immunomedics, Pfizer, Puma  Grants (to institution)  Research  Bristol‐Myers Squibb, AstaZenica, Merck  Bristol Myers‐Squibb  Honorarium  Advisory Board McQuade Speaker  Merck  Honorarium  Consulting  Novartis, La Jolla, Sierra  Honorarium  Consulting Mesa Speaker  Ingtas, CTI, Celgene,  Research Grants  PI on Trials Promedior, BLU

Moll Speaker  None  N/A  N/A

 Aduro, G1 Therapeutics, Genentech, MacroGenics, Merck, Pfizer  G1 Therapeutics  Advisory Board  AstraZeneca, Celgene,  Honorarium  Drug Saftey Nanda Speaker Corcept Therapeutics,  Honorarium Monitoring Board Genentech/Roche,  Research Grants  Research Immunomedics, Merck, OBI Pharma, Odonate Therapeutics, Pfizer, Seattle Genetics  Honorarium and travel  Speaking (one time Pai Speaker  Novartis reimbursements event)  Advisory Board and Sadeghi Speaker  Janssen, Tempus, Pfizer  Honorarium Consulting  AbbVie Inc., Amgen, AstraZeneca, Celgene, Incyte, Moderator/Planning  Speaker & Advisory Saven Pharmacyclics, Seattle  Honorarium Committee Board Genetics, Takeda Pharmaceuticals   Research Grant  Research Shustov Speaker  Kyowa Kirin, Inc.  Consulting Fees  Consulting/Speaker Moderator/Planning Torrey  None  N/A  N/A Committee

Trockel Speaker  None  N/A  N/A

 Instrumentation  Octapharma Bayer , Ergomed  Research Grants  Research Warkentin Speaker (Aspen Pharma), VLS Behring,  Consulting Fees  Consulting Alexion, Law firms  AstraZeneca, Genentech(Roche), Inivata,  Honorarium  Advisory Board West Speaker LOXO, Merck, Takeda  Honorarium  Speaker  AstraZeneca, Merck, Takeda

Woodward Speaker  Genomic Health  Honorarium  Speaker

 AbbVie, Astellas, AstraZeneca, Moderator/Planning Celgene, Genentech, Gilead  Speaker & Advisory Xavier  Honorarium Committee Sciences, Incyte, Seattle Board & Consultant Genetics  Genentech/Roche, GlaxoSmithKline, , Inc., Celgene Corporation, Janssen, , Amgen, Takeda Pharmaceuticals, Inc.,  Consulting Fees  Consultant Zelenetz Speaker Novartis, Nanostring  Research Funding  Clinical Trials Technology, Portola Pharmaceuticals, Adaptive Biotech  GlaxoSmithKline, Janssen, Roche, Gilead Sciences, Inc., Review of all CME CME Committee  None  N/A  N/A content Plan, manage, Scripps Conference implement, and  None  N/A  N/A Services & CME reconcile activity

Faculty Disclosure

Glossary of Terms

Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12‐month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or service of a commercial interest with which he/she has a financial relationship.

Z:\Clinical Research Services\Conference Folder\Conferences\Annual Courses\HemOnc 202\2020\Faculty\Disclosures\5 Faculty Disclosure Grid for Onsite‐ HEMONC2020.docx